Review of immunotherapy in rheumatoid arthritis
In the present state of knowledge about the immunopathology of rheumatoid arthritis (RA), the failure to eliminate an unknown antigen has been postulated in several models. A defective macrophage function might be the cause of the persistence of non-degradable bacterial fragments (peptidoglycan) in the macrophage after successful phagocytosis and so produce a paradoxical hyperinflammatory response due to the continued existence of a positive tendency to inflammation1. In the infective theories, there is either short-term infection altering cells or tissue antigens and the infective agent then disappears leaving a self-perpetuating auto-immune response to altered self-antigens, or the infection can be persistent and is then responsible for perpetuation of pathology.
KeywordsRheumatoid Arthritis Adverse Reaction White Blood Cell Count Mouth Ulcer Immunological Impairment
Unable to display preview. Download preview PDF.
- 2.Harmion, B. P. (1978). Infection, autoimmunity and rheumatoid arthritis. In Zvaifler, N. J.(ed.) Clinics in Rheumatic Diseases. Immunology, pp. 565–586. (London, Philadelphia, Toronto: Saunders)Google Scholar
- 3.Symoens, J. and Rosenthal, M. (1977). Levamisole in the modulation of the immune response : the current experimental and clinical state. J. Reticulo-endothelial Soc., 21, 175Google Scholar
- 4.Trabert, U., Rosenthal, M. and Muller, W. (1976). The effect of levamisole on adjuvant arthritis in the rat. J Rheumatol., 3, 166Google Scholar
- 5.Symoens, J., De Cree, J., Van Bever, W. and Janssen, P. A. J. (1979). Pharmacological Properties of Drug Substances. Vol. 2. (Washington: American Pharmaceutical Association Academy of Pharmaceutical Sciences)Google Scholar
- 8.Di Perri, T., Auteri, A., Pasini, F. L. et al. (1978). A weekly oral dose of levamisole in the treatment of rheumatoid arthritis associated with E-rosette lymphocyte reduction. Eur. J. Rheumatol. 1, 155Google Scholar
- 9.Veys, E.M. and Mielants, H. (1978). Early detection of high-risk rheumatoid arthritis patients under one day/week levamisole administration. Eur. J. Rheumatol., 1, 261Google Scholar
- 10.Multicenter Study Group (1978). A multicentre randomized double-blind study comparing two dosages of levamisole in rheumatoid arthritis. J. Rheumatol., 5 (Suppl. 4), 5Google Scholar
- 11.Mielants, H. and Veys, E. M. (1978). A study of the hematological side-effects of levamisole in rheumatoid arthritis, with recommendations. J. Rheumatol., 5 (Suppl. 4), 77Google Scholar
- 12.Symoens, J., Veys, E., Mielants, H. and Pinals, R. (1979). Adverse reactions to levamisole. Cancer Treatment Rep., 62, 1721Google Scholar
- 14.Veys, E. M. and Mielants, H. (1978). Experience and recommendations for treatment schedule of levamisole in rheumatoid arthritis. J. Rheumatol., 5 (Suppl. 4), 31Google Scholar
- 15.Renoux, G. and Renoux (1977). Roles of the imidazole or thiol moiety on the immunostimulant action of levamisole. In Chirigos, M. A. (ed.) Control of Neoplasia by Modulation of the Immune System, pp. 67–80. (New York : Raven Press)Google Scholar
- 17.Goldstein, G. (1978). Mode of action of levamisole. J. Rheumatol., 5 (Suppl. 4), 143Google Scholar